An ideal target for immunotherapy should encompass various characteristics such as frequent overexpression in a sufficient percentage of cancer cells (preferentially or exclusively) versus normal cells and a function whose disruption may represent an advantage itself [i.e., the transcription factor, brachyury, a new BC vaccine target (2)]. This evidence concerns the gene TBX1 and cancer.